Disability in patients with end‐stage liver disease: Results from the functional assessment in liver transplantation study

Mariya L. Samoylova, Kenneth E. Covinsky, Marta Haftek, Selena Kuo, John P. Roberts, Jennifer C. Lai – 24 November 2016 – Cirrhosis leads to sarcopenia and functional decline that can severely impact one's ability to function at home and in society. Self‐reported disability scales to quantify disability—Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)—are validated to predict mortality in older adults.

Reply

Marco Laudo, Matteo Ravaioli, Gaetano Manna, Giorgia Comai, Matteo Cescon, Massimo Gaudio, Valentina Bertuzzo, Chiara Zanfi, Alessandro Cucchetti, Antonio Daniele Pinna – 24 November 2016

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study

Elisabeth M. G. de Vries, Manon de Krijger, Martti Färkkilä, Johanna Arola, Peter Schirmacher, Daniel Gotthardt, Benjamin Goeppert, Palak J. Trivedi, Gideon M. Hirschfield, Henriette Ytting, Ben Vainer, Henk R. van Buuren, Katharina Biermann, Maren H. Harms, Olivier Chazouilleres, Dominique Wendum, Astrid D. Kemgang, Roger W. Chapman, Lai Mun Wang, Kate D. Williamson, Annette S. H. Gouw, Valerie Paradis, Christine Sempoux, Ulrich Beuers, Stefan G. Hübscher, Joanne Verheij, Cyriel Y.

A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus–infected mongolians

Xiaohua Chen, Odgerel Oidovsambuu, Ping Liu, Rosslyn Grosely, Menashe Elazar, Virginia D. Winn, Benjamin Fram, Zhang Boa, Hongjie Dai, Bekhbold Dashtseren, Dahgwahdorj Yagaanbuyant, Zulkhuu Genden, Naranbaatar Dashdorj, Andreas Bungert, Naranjargal Dashdorj, Jeffrey S. Glenn – 23 November 2016 – Hepatitis delta virus (HDV) causes the most severe form of human viral hepatitis. HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with HBV surface antigen envelope proteins.

Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis

Matthew J. Klebanoff, Kathleen E. Corey, Jagpreet Chhatwal, Lee M. Kaplan, Raymond T. Chung, Chin Hur – 23 November 2016 – Nonalcoholic steatohepatitis (NASH) affects 2%‐3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state‐transition model, our analysis assessed the effectiveness and cost‐effectiveness of surgery to manage NASH.

Subscribe to